SCHEMBL6411225

SCHEMBL6411225

O=c1[nH]c2ccc(CCCN3CCC(c4ccccc4)CC3)cc2c2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 7/20 0.63
PARP2 Q9UGN5 3/20 0.60
SIGMAR1 Q99720 4/20 0.57
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2D6 P10635 1/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
KMT2A Q03164 1/20 0.53
CHRNA7 P36544 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6407850 0.77 PARP1 (1.00) PARP1
Hydrochloric Acid SCHEMBL6408278 0.77 PARP1 (0.66) PARP1PARP2MEN1KMT2A
SCHEMBL8958326 0.77 SIGMAR1 (0.67) SIGMAR1MEN1TP53CYP1A2CYP3A4
SCHEMBL8109444 0.76 SIGMAR1 (0.58) SIGMAR1MEN1TP53CYP1A2CYP3A4
SCHEMBL6411446 0.75 PARP1 (0.62) PARP1PARP2
SCHEMBL14981676 0.75 PARP1 (1.00) PARP1PARP2CHRNA7
SCHEMBL9521523 0.75 SIGMAR1 (1.00) SIGMAR1MEN1TP53CYP1A2CYP3A4
SCHEMBL6408260 0.74 PARP1 (1.00) PARP1SIGMAR1CYP1A2CYP3A4TSHR
SCHEMBL8109930 0.73 HTR1A (0.69) SIGMAR1MEN1TP53CYP1A2CYP3A4
SCHEMBL6405478 0.72 PARP1 (0.54) PARP1PARP2MEN1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171101-A1 Phenanthridinones as parp inhibitors FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171101-A1 Phenanthridinones as parp inhibitors PARP1, PARP11, PARP2 PARP1 1/4885PARP2 3/4885SIGMAR1 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.